Chemotherapy, Cancer, Cardiotoxicity, Physioflow Clinical Trial
Official title:
PhysioFlow Use in Longterm Screening and Evaluation of Cardiotoxicity in Chemotherapy
PULSE-ECCho will focus on trying to detect cardiotoxicity in cancer patients receiving chemotherapy early on in order to avoid irreversible damage. In addition to that, we will test if the PhysioFlow is non-inferior to the conventional MUGA scan.
Our objective is to compare the PhysioFlow to the MUGA scan and see if the results are
statistically the same using both techniques. This is what is known as a non-inferior study.
The advantage of PhysioFlow is that it is non-invasive, fast and it is done at the bedside
or while the patient is receiving his or her chemotherapy.
The patient will be tested with the MUGA scan, as per the standard of care, before
chemotherapy is initiated and at every 3 months. The patient will also be tested with the
PhysioFlow at the same dates of the MUGA scan. In addition to that, the patients will be
tested at each chemotherapy cycle with the PhysioFlow.
Should the PhysioFlow indicate the patient has a cardiac toxicity as the patient is
receiving chemotherapy, the results will be confirmed with the MUGA scan.
;
Observational Model: Cohort, Time Perspective: Prospective